论文部分内容阅读
Background: Cancer stem cells (CSCs) are demonstrated to be rise from a small subpopulation of primary cells,which are able to generate tumor cell populations and resistance to conventional cancer therapies,resulting in tumor relapse.Immunotherapy strategies targeting glioma stem cells (GSC) hold promise for the management of malignant glioma.However,the effectiveness of dendritic cell (DC) vaccine isrestricted.In this study,we attempted to target glioma stem cells using DC-based immunotherapy in GL261glioma cell line as a cancer model in mouse and to evaluate the effectiveness between GSC+DC vaccine andtraditional adherent glioma cell (AGC) + DC vaccine.